QualTex Laboratories offers two COVID-19 antibody assays
QualTex Laboratories is up and running with two assays to detect the presence of COVID-19 antibodies in the bloodstream.
QualTex Laboratories, a subsidiary of nonprofit BioBridge Global, has been performing the SARS-CoV-2 IgG Antibody ELISA assay since April. A second assay, the Abbott Laboratories Architect Antibody assay, went into full-scale production for a QualTex customer on June 8.
“These two assays are part of our continuing commitment to public health,” said Ward Carter, Chief Operating Officer of QualTex Laboratories. “They give blood centers the information to potentially save lives during the COVID-19 pandemic by helping to identify potential COVID-19 convalescent plasma donors.”
- The Abbott assay checks blood samples for the presence of antibodies to SARS-CoV-2. It is a high-throughput test suitable for clinical laboratory use. Unlike current point-of-care tests, it has a high accuracy rate: 99.4%.
- The SARS-CoV-2 IgG Antibody ELISA assay tests for the concentration of antibodies to SARS-CoV-2. It provides titer result detection of the IgG antibody anti-RBD, which is a portion of the receptor-binding domain found on human coronavirus spike proteins. This assay is not for diagnostic use.
Both tests can be used in the process of identifying potential convalescent plasma donors. The Abbott assay determines if a blood donor may have been exposed to the virus that causes COVID-19. The SARS-CoV-2 IgG Antibody ELISA assay determines if donors have high enough level of antibodies in their plasma to have an impact when their donated plasma is transfused into seriously ill patients.